Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CBP-1203
- Development stage
- Preclinical
- Lead developer
- Coherent Biopharma
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
CBP-1203 is an investigational bispecific antibody-drug conjugate (ADC) developed by Coherent Biopharma using its proprietary Bi-XDC technology platform. It is designed to treat solid cancers by delivering a radioactive isotope payload directly to tumor cells. By utilizing a bispecific targeting approach, the drug aims to enhance specificity and therapeutic efficacy through the delivery of targeted radiotherapy while minimizing off-target effects on healthy tissue. The specific antigen targets for CBP-1203 have not been disclosed by the developer.
Beyond the preview
Go deeper on CBP-1203.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CBP-1203.